TransMedics Group (NASDAQ:TMDX) Shares Gap Up to $144.56

TransMedics Group, Inc. (NASDAQ:TMDX) shares gapped up prior to trading on Friday . The stock had previously closed at $144.56, but opened at $155.22. TransMedics Group shares last traded at $154.70, with a volume of 398,322 shares traded.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Morgan Stanley lifted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Cantor Fitzgerald assumed coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target on the stock. Canaccord Genuity Group upped their price objective on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Stephens lifted their target price on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Robert W. Baird started coverage on shares of TransMedics Group in a report on Tuesday. They issued an “outperform” rating and a $200.00 target price for the company. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $174.30.

TransMedics Group Stock Performance

The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm has a market cap of $5.19 billion, a price-to-earnings ratio of -453.79 and a beta of 1.99. The firm has a fifty day simple moving average of $156.02 and a two-hundred day simple moving average of $130.77.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. During the same period last year, the business earned ($0.03) EPS. TransMedics Group’s revenue for the quarter was up 117.7% on a year-over-year basis. On average, analysts expect that TransMedics Group, Inc. will post 1.23 EPS for the current year.

Insider Activity

In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares in the company, valued at approximately $27,587,352.18. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock valued at $9,650,880 over the last ninety days. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its holdings in shares of TransMedics Group by 10.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock valued at $31,358,000 after buying an additional 38,951 shares during the period. Vanguard Group Inc. lifted its holdings in TransMedics Group by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after acquiring an additional 50,673 shares during the period. Alpha DNA Investment Management LLC acquired a new position in TransMedics Group in the fourth quarter valued at approximately $500,000. Deerfield Management Company L.P. Series C purchased a new stake in TransMedics Group in the 2nd quarter worth approximately $1,400,000. Finally, Russell Investments Group Ltd. grew its stake in shares of TransMedics Group by 337,462.5% during the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after purchasing an additional 26,997 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.